CellSource Co

CellSource Co P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of CellSource Co (4880.T) as of Oct 27, 2026 is 26.81. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 78.93 — a change of -66.03% (lower).

P/FCF

26.81

YoY

-66.03%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of CellSource Co is 2025 26.81 . P/FCF (Price-to-Free-Cash-Flow Ratio) of CellSource Co was 2024 78.93 . It decreases by -66.03% lower compared to the previous year.

The CellSource Co P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
41.10 JPY
Jan 1, 2019
53.52 JPY
Jan 1, 2020
25.89 JPY
Jan 1, 2021
9.22 JPY
Jan 1, 2022
10.32 JPY
Jan 1, 2023
15.59 JPY
Jan 1, 2024
78.93 JPY
Jan 1, 2025
26.81 JPY
The CellSource Co P/FCF history
YEARP/FCFYoY
26.81-66.03%
78.93+406.38%
15.59+50.99%
10.32+12.02%
9.22-64.41%
25.89-51.62%
53.52+30.21%
41.10-46.02%
76.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of CellSource Co is 26.81 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of CellSource Co changed from 78.93 to 26.81, representing a -66.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) CellSource Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s CellSource Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — CellSource Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — CellSource Co